Abstract
Many drugs for the treatment of hypercholesterolemia are targeting the enzymes involved in human cholesterol biosynthesis pathway. Squalene synthase, the rate-limiting enzyme located at the downstream of cholesterol synthesis pathway, has become a better candidate to develop next-generation hypocholesterolemia drugs. In the present study, we cloned and expressed the recombinant human squalene synthase (hSQS) as the lure to isolate potential peptide inhibitors from screening the conformation-constrained phage-displayed cyclic peptide c7c library. Their binding capabilities were further estimated by ELISA. Their pharmaceutical potentials were then analyzed through molecular modeling and the ADMET property evaluations. Four ennea-peptides and nine tetra-peptides were finally synthesized to evaluate their inhibitory potentials toward hSQS. The results indicate that the ennea-peptide CLSPHSMFC, tetra-peptides SMFC, CKTE, and WHQW can effectively inhibit hSQS activities (IC50 values equal to 64, 76, 87, and 90 μM, respectively). These peptides may have potentials to develop future cholesterol-lowering therapeutics. The ligand-protein interaction analysis also reveals that the inner hydrophobic pocket could be a more critical site of hSQS.
Similar content being viewed by others
Abbreviations
- ELISA:
-
Enzyme-linked immunosorbent assay
- hHMGR:
-
Human 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- hSQS:
-
Human squalene synthase
- IPTG:
-
Isopropyl β-d-1-thiogalactopyranoside
- LDL-R:
-
Low-density lipoprotein receptor
- SDS-PAGE:
-
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
References
Steinberg, D., & Gotto, A. M. (1999). Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. Journal of the American Medical Association, 282, 2043–2050.
Goldstein, J. L., & Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature, 343, 425–430.
Brown, A. S., Bakker-Arkema, R. G., Yellen, L., Henley, R. W., Guthrie, R., Campbell, C. F., Koren, M., Woo, W., McLain, R., & Black, D. M. (1998). Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. Journal of the American College of Cardiology, 32, 665–672.
Hsu, I., Spinler, S. A., & Johnson, N. E. (1995). Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. The Annals of Pharmacotherapy, 29, 743–759.
Satoh, K., Yamato, A., Nakai, T., Hoshi, K., & Ichihara, K. (1995). Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. British Journal of Pharmacology, 116, 1894–1898.
Ichihara, K., Satoh, K., & Abiko, Y. (1993). Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. Journal of Cardiovascular Pharmacology, 22, 852–856.
Liao, J. K. (2011). Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins? Circulation, 123, 1925–1928.
Pandit, J., Danley, D. E., Schulte, G. K., Mazzalupo, S., Pauly, T. A., Hayward, C. M., Hamanaka, E. S., Thompson, J. F., & Harwood, H. J. (2000). Crystal structure of human squalene synthase. A key enzyme in cholesterol biosynthesis. Journal of Biological Chemistry, 275, 30610–30617.
Stein, E. A., Bays, H., O’Brien, D., Pedicano, J., Piper, E., & Spezzi, A. (2011). Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation, 123, 1974–1985.
Singh, B. P., Vij, S., & Hati, S. (2014). Functional significance of bioactive peptides derived from soybean. Peptides, 54, 171–179.
Cho, S. J., Juillerat, M. A., & Lee, C. H. (2007). Cholesterol lowering mechanism of soybean protein hydrolysate. Journal of Agricultural and Food Chemistry, 55, 10599–10604.
Smith, G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science, 228, 1315–1317.
Shiuan, D., Lin, H. K., Chen, Y. H., Chang, D. K., Huang, K. J., & Farh, L. (2015). Exploration of peptide inhibitors of human squalene synthase through molecular modeling and phage display technique. Applied Biochemistry and Biotechnology, 178, 312–323.
O’Neil, K. T., Hoess, R. H., Jackson, S. A., Ramachandran, N. S., Mousa, S. A., & DeGrado, W. F. (1992). Identification of novel peptide antagonists for GPIIb/ IIIa from a conformationally constrained phage peptide library. Proteins, 14, 509–515.
McLafferty, M. A., Kent, R. B., Ladner, R. C., & Markland, W. (1993). M13 bacteriophage displaying disulfide-constrained microproteins. Gene, 128, 29–36.
Liu, C.I., Liu, Y., Song, G.Y., Yin, F., Hensler, M.E., Jeng, W.Y., Nizet, V., Wang, A.H.J., & Oldfield, E. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science, 319, 1391–1394.
Lin, S. H., Chang, D. K., Chou, M. J., & Shiuan, D. (2015). Peptide inhibitors of human HMG-CoA reductase as potential hypocholesterolemic agents. Biochemistry and Biophysical Research Communications, 456, 104–109.
Yang, W. J., Lai, J. F., Peng, K. C., Chiang, H. J., Weng, C. N., & Shiuan, D. (2005). Epitope mapping of Mycoplasma hyopneumoniae using phage displayed peptide libraries and the immune responses of the selected phagotopes. Journal of Immunological Methods, 304, 15–29.
Lin, K. C., Chen, C. Y., Huang, K. J., Chang, C. W., Lin, S. P., Chang, D. K., Lin, M. R., & Shiuan, D. (2012). A dodecapeptide (YQVTQSKVMSHR) exhibits antibacterial effect and induces cell aggregation in Escherichia coli. Applied Microbiology and Biotechnology, 94, 755–762.
Venkatachalam, C. M., Jiang, X., Oldfield, T., & Waldman, M. (2003). LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. Journal of Molecular Graphics & Modeling, 21, 289–307.
Tansey, T. R., & Shechter, I. (2000). Structure and regulation of mammalian squalene synthase. Biochimica et Biophysics Acta, 1529, 49–62.
Stevens, D. (2003). Methods for determining squalene synthase activity. US Patent. 2003; US 20030157583 A1.
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248–254.
van Meerloo, J., Kaspers, G. J., & Cloos, J. (2001). Cell sensitivity assays: the MTT assay. Methods in Molecular Biology, 731, 237–245.
Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: current status and future directions. Drug Discovery Today, 20, 122–128.
Torchilin, V. P., & Lukyanov, A. N. (2003). Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discovery Today, 8, 259–266.
Acknowledgments
This work was partially supported by grants from the Ministry of Science and Technology, Taiwan, ROC (NSC97-2311-B259-04-MY3 to D. Shiuan, MOST 103-2113-M-259-019 to D. F. Tai and NSC99-2113-M-001-024-MY3 to D. K. Chang.).
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 846 kb)
Rights and permissions
About this article
Cite this article
Shiuan, D., Chen, YH., Lin, HK. et al. Discovering Peptide Inhibitors of Human Squalene Synthase Through Screening the Phage-Displayed Cyclic Peptide c7c Library. Appl Biochem Biotechnol 179, 597–609 (2016). https://doi.org/10.1007/s12010-016-2016-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-016-2016-9